NO20083737L - Hydroksysubstituerte 2-azetidinoner som er anvendbare som hypokolesterolemiske midler - Google Patents

Hydroksysubstituerte 2-azetidinoner som er anvendbare som hypokolesterolemiske midler

Info

Publication number
NO20083737L
NO20083737L NO20083737A NO20083737A NO20083737L NO 20083737 L NO20083737 L NO 20083737L NO 20083737 A NO20083737 A NO 20083737A NO 20083737 A NO20083737 A NO 20083737A NO 20083737 L NO20083737 L NO 20083737L
Authority
NO
Norway
Prior art keywords
substituted
hydroxy
hypocholesterolemic agents
azetidinones useful
cholesterol
Prior art date
Application number
NO20083737A
Other languages
English (en)
Inventor
Harry R Davis
James E Patrick
Anima Ghosal
Shmuel Zbaida
Swapan K Chowdhury
Robert M Iannucci
Wenqing Feng
Kevin B Alton
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22973953&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083737(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20083737L publication Critical patent/NO20083737L/no
Application filed by Schering Corp filed Critical Schering Corp

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Hypokolesterolemiske sukkersubstitu-erte 2-azetidinon-forbindelser og fremgangsmåte for å senke kolesterol ved å administrere forbindelsen, farmasøytiske preparater som inneholder den og kombinasjonen av et sukkersubstituert kolesterolsenkende 2-azetidinon og en kolesterolbiosynteseinhibitor for behandling og forhindring av aterosklerose.
NO20083737A 2000-12-20 2008-08-29 Hydroksysubstituerte 2-azetidinoner som er anvendbare som hypokolesterolemiske midler NO20083737L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25687500P 2000-12-20 2000-12-20
PCT/US2001/049127 WO2002050090A1 (en) 2000-12-20 2001-12-17 Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents

Publications (1)

Publication Number Publication Date
NO20083737L true NO20083737L (no) 2003-08-19

Family

ID=22973953

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20032806A NO326981B1 (no) 2000-12-20 2003-06-19 Sukkersubstituerte 2-azetidinoner anvendelige som hypokolesterolemiske midler, farmasoytisk preparat og anvendelse av forbindelsene for fremstilling av et medikament
NO20083737A NO20083737L (no) 2000-12-20 2008-08-29 Hydroksysubstituerte 2-azetidinoner som er anvendbare som hypokolesterolemiske midler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20032806A NO326981B1 (no) 2000-12-20 2003-06-19 Sukkersubstituerte 2-azetidinoner anvendelige som hypokolesterolemiske midler, farmasoytisk preparat og anvendelse av forbindelsene for fremstilling av et medikament

Country Status (34)

Country Link
US (1) US20020137690A1 (no)
EP (1) EP1347987B1 (no)
JP (2) JP4351842B2 (no)
KR (1) KR100883461B1 (no)
CN (1) CN100475829C (no)
AR (1) AR035611A1 (no)
AT (2) ATE369334T1 (no)
AU (2) AU3104902A (no)
BR (1) BR0116212A (no)
CA (1) CA2432798C (no)
CY (1) CY1106912T1 (no)
CZ (1) CZ302193B6 (no)
DE (2) DE60106489T2 (no)
DK (2) DK1593670T3 (no)
EC (1) ECSP034659A (no)
ES (2) ES2230385T3 (no)
GE (1) GEP20053548B (no)
HU (1) HUP0302269A3 (no)
IL (1) IL155771A0 (no)
MA (1) MA26975A1 (no)
MX (1) MXPA03005671A (no)
MY (1) MY129148A (no)
NO (2) NO326981B1 (no)
NZ (1) NZ525722A (no)
PE (1) PE20020718A1 (no)
PL (1) PL208242B1 (no)
PT (2) PT1593670E (no)
RU (1) RU2297422C2 (no)
SI (2) SI1347987T1 (no)
SK (1) SK286703B6 (no)
TR (1) TR200402758T4 (no)
TW (1) TWI316942B (no)
WO (1) WO2002050090A1 (no)
ZA (1) ZA200303694B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
IL157552A0 (en) 2001-03-28 2004-03-28 Schering Corp Enantioselective synthesis of azetidinone intermediate compounds
EP1429756B1 (en) 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
JP2006508188A (ja) 2002-11-06 2006-03-09 シェーリング　コーポレイション 脱髄の処置のためのコレステロール吸収インヒビター
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1522541A1 (en) * 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
CA2550215A1 (en) * 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
WO2005062824A2 (en) 2003-12-23 2005-07-14 Merck & Co., Inc. Anti-hypercholesterolemic compounds
JP2008514718A (ja) * 2004-09-29 2008-05-08 シェーリング コーポレイション 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
BRPI0708556A2 (pt) * 2006-03-06 2011-05-31 Teva Pharma composição de ezetimiba
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
CN104803957A (zh) * 2007-04-02 2015-07-29 泰拉科斯有限公司 苄基化糖苷衍生物及其用法
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
CN102388059B (zh) * 2009-02-11 2015-03-04 陶氏益农公司 杀虫组合物
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
EP2414529A2 (en) 2009-04-01 2012-02-08 Matrix Laboratories Ltd Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
KR101102749B1 (ko) * 2009-11-30 2012-01-05 최길용 곱셈 학습기
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
CN105055404B (zh) * 2015-08-19 2017-07-18 四川大学 Hmgcs2抑制剂在制备治疗可卡因成瘾的药物中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
DE69621952T2 (de) * 1995-10-31 2003-01-16 Schering Corp., Kenilworth Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
AUPQ342599A0 (en) * 1999-10-14 1999-11-04 University Of Melbourne, The Conjugates and uses thereof

Also Published As

Publication number Publication date
CN1483039A (zh) 2004-03-17
KR20030063414A (ko) 2003-07-28
AU3104902A (en) 2002-07-01
HUP0302269A3 (en) 2009-08-28
EP1347987A1 (en) 2003-10-01
TWI316942B (en) 2009-11-11
SI1347987T1 (en) 2005-02-28
MA26975A1 (fr) 2004-12-20
JP2004516299A (ja) 2004-06-03
PE20020718A1 (es) 2002-08-09
JP4351842B2 (ja) 2009-10-28
SK286703B6 (sk) 2009-03-05
GEP20053548B (en) 2005-06-27
CZ20031674A3 (cs) 2003-10-15
RU2297422C2 (ru) 2007-04-20
WO2002050090A1 (en) 2002-06-27
AU2002231049B2 (en) 2006-07-20
DE60106489T2 (de) 2005-10-13
CY1106912T1 (el) 2012-09-26
DE60106489D1 (de) 2004-11-18
NO326981B1 (no) 2009-03-30
PT1593670E (pt) 2007-11-08
CA2432798C (en) 2007-02-27
ATE369334T1 (de) 2007-08-15
RU2003122520A (ru) 2005-02-27
KR100883461B1 (ko) 2009-02-16
DE60129863T2 (de) 2008-04-30
MY129148A (en) 2007-03-30
BR0116212A (pt) 2003-12-30
DK1593670T3 (da) 2007-11-05
ZA200303694B (en) 2004-08-13
EP1347987B1 (en) 2004-10-13
NZ525722A (en) 2004-11-26
HK1084945A1 (en) 2006-08-11
JP2009132745A (ja) 2009-06-18
DK1347987T3 (da) 2005-01-31
NO20032806L (no) 2003-08-19
IL155771A0 (en) 2003-12-23
ES2287826T3 (es) 2007-12-16
WO2002050090A8 (en) 2004-04-15
PL363237A1 (en) 2004-11-15
HUP0302269A2 (hu) 2003-10-28
CN100475829C (zh) 2009-04-08
SK7702003A3 (en) 2003-10-07
PL208242B1 (pl) 2011-04-29
ATE279425T1 (de) 2004-10-15
CA2432798A1 (en) 2002-06-27
MXPA03005671A (es) 2003-10-06
HK1056735A1 (en) 2004-02-27
PT1347987E (pt) 2005-01-31
NO20032806D0 (no) 2003-06-19
US20020137690A1 (en) 2002-09-26
DE60129863D1 (de) 2007-09-20
AR035611A1 (es) 2004-06-16
TR200402758T4 (tr) 2004-11-22
ES2230385T3 (es) 2005-05-01
ECSP034659A (es) 2003-07-25
CZ302193B6 (cs) 2010-12-08
SI1593670T1 (sl) 2007-12-31

Similar Documents

Publication Publication Date Title
MY129148A (en) Sugar-substituted 2-azetidinones useful as hypocholestrolemic agents
MY114803A (en) Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
TWI320406B (en) Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
BG108168A (en) Enantioselective synthesis of azetidinone intermediate compounds
YU65802A (sh) Derivati azetidina, njihovo dobivanje i farmaceutske smeše koje ih sadrže
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
WO2002058732A3 (en) Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
WO2004037181A3 (en) Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
WO2005046797A3 (en) Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
NO20065075L (no) Ikke-nukleosidbaserte revers-transkriptase-inhibitorer.
HRP20090159T1 (en) Use of glucosidase inhibitors for therapy of mucovisidosis
IL159412A0 (en) A synergistic pharmaceutical combination for the prevention or treatment of diabetes
AU2003223340A8 (en) Certain pharmaceutically useful substituted aminoalkyl heterocycles
WO2005007124A3 (en) Substituted dihydropyrimidine inhibitors of calcium channel function
AU2001282871A1 (en) Antithrombotic agents
SG141430A1 (en) Substituted pyrrole derivatives and their use as hmg-co inhibitors
AU2002339158A1 (en) 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors
HRP20090187T1 (en) Bengamide derivatives and use thereof for the treatment of cancer
AU2002212241A1 (en) Method for producing chiral compounds
TH39048B (th) 2-อะเซติดิโนนที่ถูกแทนที่ด้วยน้ำตาลที่มีประ?โยชน์เป็นสารภาวะเลือดมีคลอเลสเตอรอลต่ำกว่าปกติ(Sugar-Substituted 2-Azetidinones Useful As Hypocholesterolemic Agents)
WO2003090737A3 (en) Methods and compositions for treatment of cancer pain

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP, US

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY

FC2A Withdrawal, rejection or dismissal of laid open patent application